Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH
Biomarker Research volume 3, Article number: 15 (2015)
Mutations of the BCR-ABL1 fusion gene represent a well established cause of resistance to tyrosine kinase inhibitors. Among the different mutations identified T315I is of particular concern since it is not effectively targeted by the majority of Tyrosine Kinase Inhibitors so far available. We developed a novel assay based on peptide nucleic acid (PNA) technology coupled to immunofluorescence microscopy (PNA-FISH) for the specific detection at a single cell level of BCR-ABL T315I mutation thus improving both, diagnostic resolution and the study of clonal prevalence. Furthermore we developed an additional method based on PNA directed PCR-clamping for the fast and easy detection of the mutation.
The PNA directed PCR clamping allows to detect an amount of mutated template as low as 0.5 %. This method is highly sensitive, specific and cheap and could be applied even in laboratory not equipped for more sophisticated analysis. Furthermore, the PNA FISH method allows to identify a small amount of progenitor cells still present after therapy with specific inhibitors.
We present here two different methods based on PNA for the detection of T315I useful for different purposes. PNA-FISH can be used to study clonal evolution. In addition, this method could help in the study of compound mutations being able to identify two different mutations in a single cell. PNA directed PCR clamping although not superior to sequencing can be applied worldwide even in laboratory not equipped to search for mutations.
Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome (Ph+) resulting from a translocation between chromosomes 9 and 22 . Ph chromosome gives origin to the BCR-ABL1 fusion gene coding for a constitutive active tyrosine kinase protein. Despite high response rate to specific tyrosine kinase inhibitors (TKI), primary and secondary resistance have been observed: upfront resistance is defined as lack of initial response and acquired resistance is defined as loss of an established response. BCR-ABL1 kinase domain (KD) mutations represent a well established cause of resistance to tyrosine kinase inhibitors . Among different mutations identified the frequently observed T315I is of particular concern since it is not effectively targeted by the majority of TKIs so far available . The only drug showing activity against T315I positive CML is ponatinib. 
Currently, the recommended method for BCR-ABL1 mutation detection is the sequencing of the KD . This is time consuming and it allows to reach a maximum sensitivity of 10–15 %.
The latter point represents a limit, as frequently mutated clones may be present at a lower percentage .
A relative new technique such the “ultra deep sequencing” allows to reach a very high level of sensitivity but it is far from been routinely applicable in world-wide laboratories .
The availability of a simple, sensitive and quick assay, allowing a rapid detection of the T315I mutation is therefore crucial, as the detection of this mutation represents an important element in clinical decision for CML patients.
Peptide Nucleic Acid (PNA) is a potent DNA mimic in terms of sequence specific hybridization. PNA/DNA is thermally more stable than DNA/DNA or DNA/RNA duplexes,  but PNA sequences cannot be extended by DNA polymerase . As consequence, PNA/DNA duplex suppresses DNA amplification. Furthermore, PNA/DNA hybridization shows a greater single-base-pair mismatch discrimination than the corresponding DNA/DNA duplex.
Based on this premise and previous data  we developed a novel and sensitive detection assay in order to quickly and easily identify T315I mutation in CML patients by PNA directed PCR clamping. The experimental design forecasts that both PNA and PCR primer target sites overlap, thus leading to a direct competition towards complementary DNA (Fig. 1). When perfect matching occurs PNA-template hybridization is favoured more than primer template duplex and DNA amplification is suppressed. Conversely, a single mismatch destabilizes the PNA-template duplex, favouring the hybridization between template and primer thus allowing template amplification. Competitor PNA sequence was designed to perfectly match wild-type (WT) template sequence. Therefore, when a single base pair mismatch occurs (like in the case of T315I) PNA-template stability is strongly impaired and DNA amplification favoured.
In addition, in order to identify the presence of BCR-ABL1 T315I mutation at the single-cell level, we set up a fluorescently-labelled PNA probe, coupled to FISH technology.
This method allows to distinguish single mutated cells from wild type cells in the context of Ph positive hematopoiesis. Here we report the two strategies (PNA clamping and PNA FISH) for a highly sensitive and very specific detection of BCR-ABL1 T315I, applied in the clinical setting of BCR-ABL T315I monitoring.
PNA-PCR clamping for BCR-ABL1 T315I mutation
The study was approved by the local ethic committee of San Luigi Hospital, Orbassano, Turin. After written informed consent BM aspirates were obtained from 17 imatinib resistant CML patient and 1 Ph + Acute Lymphoblastic Leukemia (ALL), all displaying T315I mutation detected by Sanger Sequencing. In addition, as negative control, 25 CML patients without mutations and 15 healthy subjects were examined. Detection of BCR-ABL1 was performed by capillary Sanger Sequencing method and analyzed by sequencing with BigDye terminator v3.1 (Applied Biosystem, Foster City, California CA) and capillary electrophoresis on ABI PRISM 3130XL (Applied Biosystem, Foster City, California CA). The sensitivity of this method was previously estimated by serial dilutions experiments to be approximately10 %.
Primer Sequences were as follow:
PNA competitor: OO-atatcatcactgagttcat-Lys
Competitor PNA sequence was designed to perfectly match WT template sequence.
PNA-PCR clamping conditions for BCR-ABL1 T315I mutation detection were as follow:
1st step PCR: 94 °C 3 min, (94 °C 30 s, 55 °C 30 s, 72 °C 1 min 40 s) for 40 cycles, 72 °C 5 min; 2nd step PCR: 94 °C 3 min, (94 °C 30 s, 65 °C 20 s, 55 °C 50 s, 72 °C 15 s) for 30 cycles. Sensitivity was assessed mixing, at different ratio, mutated (T315I) and WT template. Dilutions were as follow: 100, 20, 10, 5, 1, 0.5 and 0 % T315I mutated versus WT template. PCR amplification was carried-out in absence (−) or in presence (+) of competitor PNA, at a concentration 3× greater than primer FWD. The amplification performed without (−) PNA represents an internal positive control displaying the efficiency of template amplification.
PNA FISH for the detection of BCR-ABL1 T315I mutation
In addition, for the detection of T315I mutation in progenitor cells we set up a method based on fluorescently-labelled PNA probe (PNA FISH). CD34+ cells were enriched by magnetic cell sorting (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s protocol. PNA probe was designed on the human BCR-ABL1 T315I cDNA. The single nucleotide mismatch falls just in the middle of the sequence. The probe has been further tagged by fluorescinated dye at its amino-terminus. The sequence is as follow: Alexa488-OO-TATCATTGAGT-Lys. Detection of BCR-ABL T315 by PNA FISH was performed as previously described . At least 500 cells have been evaluated for each sample. A positive control is added in each reaction to distinguish between negative results and lack of hybridization.
Results and discussion
PNA FISH and PNA direct PCR clamping allow to detect T315I mutation in CML patients
Twelve patients displaying T315I mutations and 15 with BCR-ABL1 WT were examined either by direct DNA sequencing or by PNA directed PCR clamping displaying identical readout. The results and PCR conditions are summarized in Fig. 2 panel a. As expected, when the affinity between PNA and template is lowered due to the presence of the T315I mutation, DNA template is efficiently amplified. By contrast, in case of WT template the high affinity PNA/template duplex abolished PCR amplification. To test the sensitivity of the method, serial dilutions with WT and mutated T315I templates were performed keeping constant the total template amount. Surprisingly, the method displays a quite high sensitivity, allowing to detect amount of mutated template as low as 0.5 % (Fig. 2, panel b), which are not identified by classical sequencing allowing the identification of T315I mutation even when present at low amount. This method is highly sensitive, specific and cheap and could be applied even in laboratory not equipped for more sophisticated analysis. Five out of 17 CML patients carrying T315I, 1 Ph + ALL and 10 WT CML patients have been tested by PNA FISH.
This technique allowed us to identify T315I mutation at a single cell level. In particular we applied this technique to CD34+ cells to investigate the mutation in the progenitor cell compartment.
More in details, we found a residual amount of 3 % of CD34+ positive cells in a patient who became negative for the T315I mutation by Sanger sequencing after ponatinib treatment and acquired T317 mutation at the time of evaluation by PNA. In additional 4 patients positive for T315I mutation by Sanger sequencing, PNA FISH detected the mutation in respectively 20, 35, 45 % (Fig. 3 panel c, d) and 60 % (Fig. 3 panel a, b) of CD34+ cells. Finally in the case of Ph + ALL with increasing values of BCR-ABL1 transcript during dasatinib treatment and negative for T315I by Sanger sequencing we found about 2 % of cells with T315I mutation by PNA FISH. These cells were undetectable after hematopoietic stem cell transplant, in accordance with a progressive decrease of BCR-ABL1 transcript.
We suggest that this approach could be extended to other relevant and frequent BCR-ABL1 mutations thus allowing to drive clinical decisions after TKI failure. Importantly, it is now known that the emergence of compound mutations in a BCR-ABL1 allele usually confer ponatinib resistance. More in general, it was shown that BCR-ABL1 compound mutants confer different levels of TKI resistance , thus requiring a rational and patient adapted selection of drugs to optimize the clinical outcome. PNA-FISH allows to identify compound mutation in single cells and to predict response to therapy. Furthermore, PNA-FISH technology allows to provide an answer to many questions including the possibility of the persistence of mutated stem/progenitor cells in patients in MMR and the significance of the presence of small mutated clones at diagnosis. Finally, it allows to follow up clonal evolution during TKI therapy.
Acute lymphoblastic leukemia
Chronic myeloid leukemia
Fluorescence in situ hybridization
Magnetic activated cell sorting
Major molecular remission
Polymerase chain reaction
Peptide nucleic acid
Tyrosine kinase inhibitors
Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93–9.
Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208–15.
Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27:4204–10.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. Kantarjian H A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.
Quintás-Cardama A, Gibbons DL, Kantarjian H, Talpaz M, Donato N, Cortes J. Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1 (T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain. Leukemia. 2008;22:885–8.
Preuner S, Mitterbauer G, Mannhalter C, Herndlhofer S, Sperr WR, Valent P, et al. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, expansion, and depletion in chronic myeloid leukaemia. Eur J Cancer. 2012;48:233–6.
Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122:1634–48.
Sugimoto N, Yamamoto K, Satoh N. Positional effect of single bulge nucleotide on PNA (peptide nucleic acid)/DNA hybrid stability. Nucleic Acids Symp Ser. 1999;42:95–6.
Sugimoto N, Satoh N, Yamamoto K. Comparison of thermodynamic stabilities between PNA (peptide nucleic acid)/DNA hybrid duplexes and DNA/DNA duplexes. Nucleic Acids Symp Ser. 1999;42:93–4.
Bracco E, Rosso V, Serra A, Carnuccio F, Gaidano V, Nicoli P, et al. Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. BMC Cancer. 2013;13:348.
Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428–42.
This work was supported by a special grant from “AIRC 5 per mille” to the AGIMM group (AIRC-Gruppo Italiano Malattie Mieloproliferative); for a complete list of AGIMM investigators see at http://www.progettoagimm.it. The study was partially funded by grants from: PRIN, AIL (Associazione Italiana contro le Leucemie), and by Regione Piemonte.
The authors have no competing financial interests.
VR and RP performed the experiments. EB designed PNA and wrote the manuscript. SC performed PNA FISH. ES, CC and JP processed samples and enriched CD34+ cells. PN, MDG, VG, DG, SU, CF and GRC collected samples and analysed data. FF and GS contributed to manuscript writing and provided final approval. DC designed the experiments and wrote the manuscript. All authors read and approved the final manuscript.
Valentina Rosso and Enrico Bracco contributed equally to this work.
About this article
Cite this article
Rosso, V., Bracco, E., Pedrola, R. et al. Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. Biomark Res 3, 15 (2015). https://doi.org/10.1186/s40364-015-0039-y
- T315I mutation
- Chronic Myeloid Leukemia